Article
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
Journal of hepatology - 1 Aug 2018
Puoti Massimo, Foster Graham R, Wang Stanley, Mutimer David, Gane Edward, Moreno Christophe, Chang Ting Tsung, Lee Samuel S, Marinho Rui, Dufour Jean-Francois, Pol Stanislas, Hezode Christophe, Gordon Stuart C, Strasser Simone I, Thuluvath Paul J, Zhang Zhenzhen, Lovell Sandra, Pilot-Matias Tami, Mensa Federico J
Abstract excerpt
BACKGROUND & AIMS: Glecaprevir plus pibrentasvir (G/P) is a pangenotypic, once-daily, ribavirin-free direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection. In nine phase II or III clinical trials, G/P therapy achieved rates of sustained virologic response 12 weeks after treatment (SVR12) of 93-100% across all six major HCV genotypes (GTs). An integrated efficacy analysis of 8- and 12-week...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.